Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOSTINEX vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Treatment of hyperprolactinemic disorders (e.g., amenorrhea, galactorrhea, infertility),Prolactin-secreting pituitary adenomas (prolactinomas),Off-label: Reduction of breast engorgement postpartum (non-FDA)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
The terminal elimination half-life is 63–69 hours in healthy volunteers and 79–115 hours in patients with hyperprolactinemia, allowing once- or twice-weekly dosing. The long half-life reflects slow dissociation from D2 receptors and enterohepatic recirculation.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Extensively metabolized in the liver, primarily via hydrolysis of the acylurea bond; CYP3A4 is involved in minor hydroxylation pathways.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Cabergoline is extensively metabolized in the liver, primarily via CYP3A4. Elimination is predominantly fecal (60%) and renal (20%) as metabolites, with <4% as unchanged drug. Biliary excretion contributes to fecal elimination.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 41–42% bound to plasma proteins, primarily albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
The apparent volume of distribution is approximately 150–200 L, indicating extensive tissue distribution. In L/kg (assuming 70 kg), Vd ≈ 2.1–2.9 L/kg. This large Vd suggests sequestration in tissues, including the pituitary.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability is approximately 50–60% due to first-pass metabolism. Food does not significantly affect absorption.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No specific recommendations; use caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No specific recommendations; use caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Safety and effectiveness in pediatric patients have not been established; not recommended.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustment; monitor for orthostatic hypotension and neuropsychiatric effects.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of valvulopathy and cardiac fibrosis with long-term use, especially at high cumulative doses,May cause hypotension, syncope, or orthostatic hypotension,Monitor for pleural effusion, pulmonary fibrosis, and pericarditis,Impulse control disorders (e.g., pathological gambling, hypersexuality),Somnolence and sudden sleep onset; caution when driving
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Uncontrolled hypertension,Preeclampsia or eclampsia,Known hypersensitivity to ergot derivatives,History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food restrictions. However, high-fat meals may increase absorption, but no dose adjustment is required. Avoid alcohol due to increased risk of dizziness and gastrointestinal upset. Grapefruit juice may inhibit CYP3A4 and increase cabergoline levels; consider avoiding large quantities.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Category B: Animal studies (rats, rabbits) at doses up to 2.5 mg/kg/day showed no teratogenic effects but embryotoxicity at high doses. No adequate human studies. Post-marketing reports of spontaneous abortion and congenital anomalies (limb defects, cardiac) but causal relationship unestablished. Avoid in pregnancy unless benefit outweighs risk. Use only after excluding pregnancy and using effective contraception during treatment until 1 month after discontinuation.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Excreted into human milk. Peak milk concentration ~0.15-0.25 ng/m L after 0.25 mg oral dose. M/P ratio unknown. Due to potential for suppression of lactation and unknown infant effects, contraindicated in breastfeeding women. Discontinue nursing or avoid drug.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustments recommended due to contraindication in pregnancy. If inadvertently exposed, discontinue immediately. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy, but no formal dose adjustment studies exist. Use is not advised.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Dostinex (cabergoline) is a long-acting dopamine D2 receptor agonist used primarily for hyperprolactinemia. Its half-life of 63-69 hours allows once or twice weekly dosing. Monitor for valvular heart disease with echocardiography before and during therapy due to risk of fibrotic reactions, especially at high doses used in Parkinson's disease. Avoid concurrent use with CYP3A4 inhibitors (e.g., macrolides, azole antifungals) that can increase cabergoline levels. Titrate dose gradually to minimize orthostatic hypotension and gastrointestinal side effects.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take exactly as prescribed, typically once or twice per week; do not double doses if missed. Take with food if nausea occurs. Avoid alcohol as it may increase side effects. Report any shortness of breath, cough, chest pain, or swelling of extremities immediately (signs of valvulopathy). Do not drive or operate machinery until you know how the medication affects you, as it may cause dizziness or drowsiness. Women who may become pregnant should use effective contraception; stop cabergoline if pregnancy is confirmed. Inform all healthcare providers about this medication, including before any surgery or dental procedures. Keep out of reach of children and store at room temperature.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOSTINEX vs ABSTRAL, answered by our medical review team.
DOSTINEX is a Dopamine Agonist that works by Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOSTINEX and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOSTINEX is: 0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOSTINEX and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOSTINEX is classified as Category C. Category B: Animal studies (rats, rabbits) at doses up to 2.5 mg/kg/day showed no teratogenic effects but embryotoxicity at high doses. No adequate human studies. Post-marketing re. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.